Insys Therapeutics
1333 S Spectrum Boulevard
Suite 100
Chandler
Arizona
85286
United States
Tel: 602-910-2617
Fax: 602-910-2627
Email: info@insysrx.com
180 articles about Insys Therapeutics
-
INSYS Therapeutics Affirms Its Commitment to Sustainable Future Growth
10/30/2017
The company's CEO has released a statement regarding the events of the past few days.
-
Once again Insys has been rocked by an indictment.
-
INSYS Therapeutics to Report Third Quarter 2017 Results on Nov. 2
10/19/2017
The third quarter 2017 financial results will release on Thursday, Nov. 2, before the U.S. financial markets open.
-
Scandal-Ridden INSYS Replaced 90% of Its Original Sales Force in Makeover
10/9/2017
-
INSYS Extends ‘Compassionate Use’ Studies Of Cannabidiol (CBD) For Refractory Pediatric Epilepsy
10/9/2017
-
INSYS Completes Pharmacokinetics (PK) Study Of Intranasal Naloxone For Opioid Overdose
10/3/2017
-
INSYS Files New Drug Application (NDA) For Buprenorphine Sublingual Spray With FDA
9/29/2017
-
INSYS Hires First Corporate Communications Leader And New Investor Relations Agency
9/22/2017
-
INSYS Addresses Arizona Attorney General Complaint
9/5/2017
-
INSYS Addresses Questions Raised By Illinois Settlement
8/22/2017
-
INSYS Reports Second Quarter 2017 Results
8/3/2017
-
INSYS Announces Availability Of SYNDROS, The First And Only FDA-Approved Liquid Dronabinol, By Prescription
7/31/2017
-
INSYS To Report Second Quarter 2017 Results On August 3, 2017
7/20/2017
-
INSYS Appoints Andrew G. Long As Chief Financial Officer
7/18/2017
-
INSYS Releases Statement On Payor Interactions
7/17/2017
-
Brutal Week For INSYS As Two More Ex-Sales Reps Plead Guilty In Kickback Schemes
7/13/2017
-
INSYS Hires Four Key Pharmaceutical Industry Veterans For Leadership Positions
6/20/2017
-
INSYS Releases Statement On Its Ongoing Mission
6/5/2017
-
INSYS Sponsors Cancer Caregivers Education Program
5/26/2017
-
INSYS Announces FDA Final Product Label For Syndros
5/24/2017